KLK3 and neoplasm: Dutasteride significantly delayed the time to prostate-specific antigen (PSA) doubling compared with placebo after 2 years of treatment, along with suppressed tumour growth demonstrating an overall relative risk reduction of 59% in favour of dutasteride compared to placebo (p < 0.001) [12].